In Vitro Biology & High-throughput Chemistry, Integrated Drug Discovery, Sanofi-Aventis Deutschland GmbH, Frankfurt, Germany.
Synthetic Molecular Design, Integrated Drug Discovery, Sanofi-Aventis Deutschland GmbH, Frankfurt, Germany.
SLAS Discov. 2021 Jul;26(6):783-797. doi: 10.1177/24725552211011180. Epub 2021 May 6.
Classical high-throughput screening (HTS) technologies for the analysis of ionic currents across biological membranes can be performed using fluorescence-based, radioactive, and mass spectrometry (MS)-based uptake assays. These assays provide rapid results for pharmacological HTS, but the underlying, indirect analytical character of these assays can be linked to high false-positive hit rates. Thus, orthogonal and secondary assays using more biological target-based technologies are indispensable for further compound validation and optimization. Direct assay technologies for transporter proteins are electrophysiology-based, but are also complex, time-consuming, and not well applicable for automated profiling purposes. In contrast to conventional patch clamp systems, solid supported membrane (SSM)-based electrophysiology is a sensitive, membrane-based method for transporter analysis, and current technical developments target the demand for automated, accelerated, and sensitive assays for transporter-directed compound screening. In this study, the suitability of the SSM-based technique for pharmacological compound identification and optimization was evaluated performing cell-free SSM-based measurements with the electrogenic amino acid transporter BAT1 (SLC6A19). Electrophysiological characterization of leucine-induced currents demonstrated that the observed signals were specific to BAT1. Moreover, BAT1-dependent responses were successfully inhibited using an established in-house tool compound. Evaluation of current stability and data reproducibility verified the robustness and reliability of the applied assay. Active compounds from primary screens of large compound libraries were validated, and false-positive hits were identified. These results clearly demonstrate the suitability of the SSM-based technique as a direct electrophysiological method for rapid and automated identification of small molecules that can inhibit BAT1 activity.
经典的高通量筛选 (HTS) 技术可用于分析生物膜中的离子电流,可使用荧光、放射性和质谱 (MS) 摄取测定法进行。这些测定法为药理学 HTS 提供了快速的结果,但这些测定法的间接分析特性可能导致高假阳性命中率。因此,使用更多基于生物学靶标的正交和二次测定法对于进一步的化合物验证和优化是必不可少的。转运蛋白的直接测定技术基于电生理学,但也很复杂、耗时,并且不适用于自动化分析。与传统的膜片钳系统相比,基于固体支持膜 (SSM) 的电生理学是一种敏感的膜分析方法,当前的技术发展针对的是对转运蛋白导向化合物筛选进行自动化、加速和敏感测定的需求。在这项研究中,通过使用电活性氨基酸转运蛋白 BAT1(SLC6A19)的无细胞 SSM 测量来评估基于 SSM 的技术在药理学化合物鉴定和优化方面的适用性。用亮氨酸诱导电流进行的电生理学特性分析表明,观察到的信号是 BAT1 特有的。此外,使用内部建立的工具化合物成功抑制了 BAT1 依赖性反应。电流稳定性和数据重现性的评估验证了应用测定法的稳健性和可靠性。从大型化合物文库的初步筛选中验证了活性化合物,并鉴定了假阳性命中。这些结果清楚地表明,基于 SSM 的技术作为一种快速、自动化鉴定能够抑制 BAT1 活性的小分子的直接电生理学方法是合适的。